Alteogen Inc.
196170.KQSouth Korea
48 filed reports · 447 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
48 reports · Dec 2014 to Sep 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 11011DART | 12 | 3,655 | Dec 2014 to Dec 2025 |
| Half Year · 11012DART | 12 | 4,872 | Jun 2015 to Jun 2026 |
| Q1 · 11013DART | 12 | 4,389 | Mar 2015 to Mar 2026 |
| Q3 · 11014DART | 12 | 4,850 | Sep 2015 to Sep 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 11014 | 2026-09-30 | 2026-11-16 | 791 | Open |
| FY2026 H1 | 11012 | 2026-06-30 | 2026-08-14 | 810 | Open |
| FY2026 Q1 | 11013 | 2026-03-31 | 2026-05-15 | 687 | Open |
| FY2025 | 11011 | 2025-12-31 | 2026-03-23 | 820 | Open |
| FY2025 Q3 | 11014 | 2025-09-30 | 2025-11-14 | 405 | Open |
| FY2025 H1 | 11012 | 2025-06-30 | 2025-08-13 | 387 | Open |
| FY2025 Q1 | 11013 | 2025-03-31 | 2025-05-13 | 323 | Open |
| FY2024 | 11011 | 2024-12-31 | 2025-03-21 | 338 | Open |
| FY2024 Q3 | 11014 | 2024-09-30 | 2024-11-14 | 392 | Open |
| FY2024 H1 | 11012 | 2024-06-30 | 2024-08-14 | 384 | Open |
| FY2024 Q1 | 11013 | 2024-03-31 | 2024-05-16 | 316 | Open |
| FY2023 | 11011 | 2023-12-31 | 2024-03-18 | 543 | Open |
Financial data
447 concepts · 17,766 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS420 concepts · 17,431 facts · Dec 2011 to Sep 2026
- Stockholders Equity184 · Dec 2012 to Sep 2026
- Cash and Equivalents178 · Dec 2012 to Sep 2026
- Cost of Revenue178 · Dec 2012 to Sep 2026
- EPS (Basic)178 · Dec 2012 to Sep 2026
- EPS (Diluted)178 · Dec 2012 to Sep 2026
- Finance Income178 · Dec 2012 to Sep 2026
- Gross Profit178 · Dec 2012 to Sep 2026
- Income Tax Expense (Benefit)178 · Dec 2012 to Sep 2026
- Interest Expense178 · Dec 2012 to Sep 2026
- Issued Share Capital178 · Dec 2012 to Sep 2026
- Net Income178 · Dec 2012 to Sep 2026
- Operating Income178 · Dec 2012 to Sep 2026
- Other Current Financial Liabilities178 · Dec 2012 to Sep 2026
- Other gains178 · Dec 2012 to Sep 2026
- Other losses178 · Dec 2012 to Sep 2026
- Other Noncurrent Financial Liabilities178 · Dec 2012 to Sep 2026
- Pretax Income178 · Dec 2012 to Sep 2026
- Property, Plant & Equipment, Net178 · Dec 2012 to Sep 2026
- Retained Earnings (Accumulated Deficit)178 · Dec 2012 to Sep 2026
- Revenue178 · Dec 2012 to Sep 2026
- SG&A Expense178 · Dec 2012 to Sep 2026
- Total Assets178 · Dec 2012 to Sep 2026
- Total Comprehensive Income178 · Dec 2012 to Sep 2026
- Total Current Assets178 · Dec 2012 to Sep 2026
Segment27 concepts · 335 facts · Dec 2024 to Sep 2026
- Number of share options exercisable in share-based payment arrangement34 · Dec 2024 to Sep 2026
- Revenue28 · Dec 2024 to Sep 2026
- Revenue from rendering of services28 · Dec 2024 to Sep 2026
- Revenue from sale of goods product28 · Dec 2024 to Sep 2026
- Weighted average exercise price of share options exercisable in share-based payment arrangement26 · Dec 2024 to Sep 2026
- Number of share options granted in share-based payment arrangement24 · Dec 2024 to Sep 2026
- Revenue from sale of goods merchandise24 · Dec 2024 to Sep 2026
- Number of share options expired in share-based payment arrangement19 · Dec 2024 to Sep 2026
- Weighted average exercise price of share options granted in share-based payment arrangement16 · Dec 2024 to Sep 2026
- Issued amount, convertible preferred stock14 · Dec 2024 to Sep 2026
- Exercise price of outstanding share options12 · Dec 2025 to Sep 2026
- Number of share options outstanding in share-based payment arrangement10 · Mar 2025 to Sep 2026
- Weighted average exercise price of share options expired in share-based payment arrangement10 · Dec 2024 to Jun 2026
- Increase (decrease) in weighted average exercise price of share options through merger9 · Mar 2025 to Sep 2026
- Increase (decrease) in number of share options through merger7 · Mar 2025 to Sep 2026
- Capital commitments6 · Mar 2025 to Jun 2026
- Expected dividend as percentage, share options granted6 · Mar 2026 to Sep 2026
- Number of share options exercised in share-based payment arrangement6 · Dec 2024 to Sep 2026
- Weighted average exercise price of share options exercised in share-based payment arrangement6 · Dec 2024 to Sep 2026
- Number of share options forfeited in share-based payment arrangement4 · Sep 2025 to Sep 2026
- Option life, share options granted4 · Dec 2025 to Sep 2026
- Weighted average exercise price of share options forfeited in share-based payment arrangement4 · Sep 2025 to Sep 2026
- Increase (decrease) in number of share options due to bonus issue2 · Sep 2025 to Sep 2026
- Increase (decrease) in weighted average exercise price of share options due to bonus issue2 · Sep 2025 to Sep 2026
Segments
335 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments11 members · 227 facts
- AlteogenIncMemberOfSegmentsMemberOfDisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTableOfMember73 · Dec 2024 to Sep 2026
- AlteogenBiologicsIncMemberOfSegmentsMemberOfDisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsTableOfMember72 · Dec 2024 to Sep 2026
- AlteogenBiologicsIncMemberOfReportableSegmentsMemberOfDisclosureOfImpairmentOnDevelopmentExpenseTableOfMember20 · Dec 2024 to Sep 2026
- AlteogenBiologicsIncMemberOfSegmentsMemberOfDisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTableOfMember16 · Dec 2025 to Sep 2026
- AlteogenIncMemberOfSegmentsMemberOfDisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTableOfMember16 · Dec 2025 to Sep 2026
- AlteogenIncMemberOfSegmentsMemberOfDisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodTableOfMember7 · Dec 2025 to Sep 2026
- AlteogenBiologicsIncMemberOfSegmentsMemberOfDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTableOfMember6 · Dec 2025 to Sep 2026
- AlteogenIncMemberOfSegmentsMemberOfDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTableOfMember6 · Dec 2025 to Sep 2026
- AlteogenBiologicsIncMemberOfSegmentsMemberOfDisclosureOfShareBasedPaymentOfTheMergedCompanyTableOfMember4 · Mar 2025 to Jun 2025
- AlteogenHealthcareIncMemberOfSegmentsMemberOfIssuedAmountOfConvertibleRedeemablePreferredStockAndConvertiblePreferredStockTableOfMember4 · Dec 2024 to Dec 2025
- AlteogenBiologicsIncMemberOfSegmentsMemberOfDisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodTableOfMember3 · Mar 2026 to Sep 2026
Geographical areas2 members · 108 facts
- CountryOfDomicileMember54 · Dec 2024 to Sep 2026
- ForeignCountriesMember54 · Dec 2024 to Sep 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Alteogen Inc. (196170.KQ) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.